

Cite this: *Chem. Sci.*, 2020, **11**, 7927

All publication charges for this article have been paid for by the Royal Society of Chemistry

Chemical synthesis and biological activity of peptides incorporating an ether bridge as a surrogate for a disulfide bond†

Rui Zhao,^{‡ab} Pan Shi,^{‡a} Junyou Chen,^{‡b} Shuaishuai Sun,^b Jingnan Chen,^b Jibin Cui,^b Fangming Wu,^f Gemin Fang,^{id e} Changlin Tian,^{id a} Jing Shi,^{*a} Donald Bierer,^d Lei Liu^{id c} and Yi-Ming Li^{id *b}

Disulfide bridges contribute to the definition and rigidity of polypeptides, but they are inherently unstable in reducing environments and in the presence of isomerases and nucleophiles. Strategies to address these deficiencies, ideally without significantly perturbing the structure of the polypeptide, would be of great interest. One possible surrogate for the disulfide bridge is a simple thioether, but these are susceptible to oxidation. We report the introduction of an ether linkage into the biologically active, disulfide-rich peptides oxytocin, tachyplesin I, and conotoxin α -ImI, using an ether-containing diaminodiacid as the key building block, obtained by the stereoselective ring-opening addition reaction of an aziridine skeleton with a hydroxy group. NMR studies indicated that the derivatives with an ether surrogate bridge exhibited very small change of their three-dimensional structures. The analogs obtained using this novel substitution strategy were found to be more stable than the original peptide in oxidative and reductive conditions; without a loss of bioactivity. This strategy is therefore proposed as a practical and versatile solution to the stability problems associated with cysteine-rich peptides.

Received 27th April 2020

Accepted 6th July 2020

DOI: 10.1039/d0sc02374d

rsc.li/chemical-science

Introduction

Disulfide-rich polypeptides have emerged as promising drug candidates due to their excellent metabolic stability, potent activity and high target selectivity.¹ These favorable characteristics are in part due to the disulfide bonds themselves, which support the definition of the structure and influence the topological orientation of the pharmacophore, thereby imparting stability and selectivity to the peptides.² However, disulfide bonds are inherently unstable in reducing environments and in the presence of isomerases and nucleophiles, resulting in structural rearrangement of the entire peptide and a complete loss of biological activity.³ Accordingly, the replacement of this

basic structural element with a more stable, non-reducing isostere would be highly desirable; and thioether,⁴ diselenide bridge,⁵ triazole,⁶ and hydrocarbon bridge⁷ surrogates have all been proposed. In practice, however, drawbacks are associated with all of these disulfide bond surrogates. First, the rigidity and planarity of triazole and dicarba (olefin or hydrocarbon) bridges generally precludes their proper accommodation into the parent structures of peptides, changing their overall shape, properties, and activity.⁸ For example, some triazole-containing insulin analogs were poorly active due to structural distortions introduced into their backbone by the triazole moiety.^{8a} Furthermore, although thioether and selenoether bridges are similar in structure and reactivity to the native disulfides, they are also prone to oxidation, which can be problematic – some thioether-substituted conotoxin α -ImI derivatives have previously been revealed to be easily oxidized to sulfoxide, leading to a loss of activity.^{4a}

Another possible disulfide bridge isostere is an ether bridge, which in principle has several advantages over those previously mentioned. For example, ether bridges are inherently more stable than thioether bridges, are expected to be readily accommodated by the structure of the peptide, being neither rigid nor planar, and not susceptible to racemization during solid phase peptide synthesis (SPPS). However, the formation of ether bonds is difficult, especially in the context of side chain cyclization, and usually requires forcing conditions not compatible with delicate peptide functionality.⁹

^aHefei National Laboratory of Physical Sciences at Microscale, Department of Chemistry, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230009, China. E-mail: shijing@ustc.edu.cn

^bSchool of Food and Biological Engineering, Hefei University of Technology, Hefei, Anhui 230009, China. E-mail: ymli@hfut.edu.cn

^cDepartment of Chemistry, Tsinghua University, Beijing 100084, China

^dDepartment of Medicinal Chemistry, Bayer AG, Aprather Weg 18A, 42096 Wuppertal, Germany

^eSchool of Life Science, Institute of Physical Science and Information Technology, Anhui University, Hefei 230601, China

^fHigh Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei 230031, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0sc02374d

‡ These authors contributed equally to this work.



Herein, we disclose a new and practical strategy for the synthesis of cysteine-rich peptides incorporating an ether linkage as a disulfide-bond mimic using an orthogonally protected, ether-containing diaminodiacid, obtained by the stereoselective ring-opening addition reaction of an aziridine with a hydroxy group (Scheme 1).¹⁰ The utility of this strategy was exemplified in syntheses of the ether analogs of oxytocin; the bacteriostatic peptide tachyplesin I (TPI-1), which was shown to be more stable than that its wild-type (WT) counterpart under reducing conditions but just as bioactive; and an ether-substituted conotoxin α -ImI analog, which was significantly more stable in oxidative environments compared to conotoxin α -ImI analogs incorporating thioether bonds.

Results and discussion


Although ether bridge possibly has advantages over previously mentioned surrogates, the replacement of a disulfide moiety with an ether is not straightforward. The major reason for this is that whereas a disulfide bridge can be readily formed by the gentle oxidation of two proximal thiols, the reaction conditions used to construct ether bonds are relatively harsh; for example, the Williamson ether synthesis requires high temperatures, strongly basic sodium alkoxides, and prolonged reaction times.⁹ To avoid having to expose a fully-formed peptide to such forcing conditions, we envisioned pre-preparation of a diaminodiacid unit containing an ether bond, followed by its incorporation into a polypeptide by conventional SPPS. We expected that under Lewis acid catalysis, selective β -position ring-opening addition of azacyclopropane derivatives through the side chain hydroxyl groups of homoserine derivatives will construct

the key skeleton of the ether-containing diaminodiacid.¹⁰ Vederas *et al.* used a similar reaction to synthesize a natural product DAP analog which was crucial for bacterial cell wall layer formation.^{10d}


First, we synthesized aziridine derivative **1b** by cyclization of **1a** using methanesulfonyl chloride and triethylamine. To activate the aziridine for regioselective ring opening at the β -position, we chose the electron-withdrawing *p*-nitrobenzyloxycarbonyl group (*p*NZ) for nitrogen protection.¹¹ After removal of the Trt group, *p*NZ-Cl was added to obtain segment **1c**. We further obtained Fmoc-homoserine-*t*Bu **2a** as previously reported,⁴ and then successfully constructed the key intermediate **3a** containing an ether bond by reacting **2a** and **1c** in the presence of catalytic $\text{BF}_3 \cdot \text{OEt}_2$ (yield 30%). Finally, the ether-containing diaminodiacid product **4a** was obtained by removing the *t*Bu group with TFA (overall yield 3.1%, 7 steps from L-serine) (Scheme 2). Because the ether bond is slightly shorter than the disulfide bond, we further prepared a side-chain extended ether-containing diaminodiacid **4b** by coupling Fmoc-homohomoserine-*t*Bu (**2b**) with **1c**, to test the influence of linkage length on peptide bio-activity (Scheme S5†).

With ether-containing diaminodiacids in hand, we first tested their compatibility with Fmoc-based SPPS by synthesizing ether-containing analogs of oxytocin, a peptide hormone with a plethora of both physiological and psychological biological functions.¹² The synthesis of the ether-containing analog of oxytocin was attempted first. Gly, Leu and Pro were sequentially coupled to Rink amide AM resin to give **5**. Then, **4a** was condensed to the α -amino of the pendant Pro of **5** to yield **6**. Finally, the Tyr-Ile-Gln-Asn tetrapeptide was added on to the **4a** moiety of **6**. After removal of the allyl protecting group, the side-chain carboxyl group of **4a** and N-terminal amino group of Tyr were efficiently cyclized using PyAOP/MMM. Then, the *p*NZ group was removed and finally the oxytocin analog **9** was obtained after cleavage from the resin using TFA (Fig. 1a). HPLC analysis of the purified products gave rise to a single peak, and **10** was also identified by LC-MS as an oxytocin derivative containing an ether bond (Fig. 1b), HPLC analysis of purified **10** showed a single product peak, and it was identified by LC-MS as an oxytocin derivative containing an ether bond (Fig. 1b), proving that the new diaminodiacid can be readily used in SPPS. The circular dichroism (CD) spectrum confirmed that **10** had


a. previous work:



b. this work:



Scheme 1 Diaminodiacid strategy enabled the development of the first example of cysteine-rich peptide exploiting the ether-bond as disulfide-bond mimic. These ether-containing peptide mimics exhibit significant stability to both reduction and oxidation conditions.



Scheme 2 Chemical synthesis of ether-containing diaminodiacids **4a**.






Fig. 1 (a) Synthetic route for the preparation of oxytocin analog using diaminodiacid **4a**. (b) HPLC traces and ESI-MS analysis of purified oxytocin analog. (c) CD spectra of oxytocin analogue in water. (d) Backbone ensembles of 20 lowest-energy NMR structures of oxytocin analog **10** (left) and a ribbon representation of **10** (right). The C–O bridge is shown in red.

a secondary structure, very similar to that of its native counterpart (Fig. 1c).^{4c} To verify the three-dimensional structure of diaminodiacid-replaced analogue, solution NMR experiments including DQF-COSY, TOCSY, NOESY and ROESY were carried out to determine the structure of **10**. With a total of 52 NOE distance restraints (including 3 long-range NOEs) and 6 dihedral restraints, 20 lowest energy structures selected from 100 calculated structures were observed with an all heavy atom RMSD (residue 1–8) of 1.476 Å (Fig. 1d and ESI Table S1†). The ROESY cross peaks and NMR structure showed that **10** incorporated the correct Cys1–Cys6 ether bond connectivity (Fig. 1d). The overall solution NMR structure of **10** is a turning loop structure, almost identical to the native oxytocin. In our proton assignment, similar chemical shifts for Cα–H atoms were observed for native oxytocin^{4b} and **10**, except for the replaced Cys residues (Fig. S11†), thus indicating that replacement of the Cys1–Cys6 disulfide bond with an ether bond had little influence on the tertiary structure of Oxytocin.

Next, our attention turned to tachyplesin I (**TPI-1**). **TPI-1** adopts a β-sheet conformation stabilized by two cross-linked

disulfide bonds,¹³ and the folding and activity of its analogs are sensitive to the nature of the disulfide bond surrogates. For example, when the Cys7–Cys12 disulfide bond was replaced with a thioether bond, the bio-activity of the resulting **TPI-1** analog was significantly reduced compared to **TPI-1**.^{4b} Our synthesis of a **TPI-1** derivative incorporating an ether bond (**TPI-2**) in place of the Cys7–Cys12 disulfide bond is depicted in Fig. 2a. A linear peptide **11** containing **4a** was first assembled on the resin. Removal of the allyl and Fmoc groups of **11** gave peptide **12**. Cyclization using PyAOP and NMM followed by removal of the pNZ protecting group gave **13**. After condensation of the hexapeptide Lys–Trp–Cys–Phe–Arg–Val with **13**, the resulting peptide was cleaved from the resin and purified by HPLC to give the full-length peptide **14**, which was refolded under neutral conditions (33% acetonitrile, 1 : 1 GSSG/GSH, pH 7.5). HPLC and ESI-MS analysis demonstrated the purity and correct molecular weight of the ether bond substituted **TPI-2** (Fig. 2b). For comparison, wildtype (WT) **TPI-1** and **TPI-3** incorporating a side-chain containing an extra methylene group were obtained under the same conditions. Using previous reported thioether-containing diaminodiacids, we further synthesized two other **TPI-1** derivatives incorporating thioether linkages of different lengths (**TPI-4** and **TPI-5**) (Fig. 2d). The CD spectra of **TPI-1** and its ether bond analogs were measured; WT **TPI-1** was found to give rise to a positive peak at 196 nm and a negative peak at 218 nm, while the spectra of its ether bond analogs showed a weak negative absorption at 218 nm (Fig. 2c). This suggests the β-sheet structure of **TPI-2** and **TPI-3** to be less ordered than that of **TPI-1**, consistent with the previous results of thioether derivatives.^{4b} We further conducted solution NMR spectroscopy (including DQF-COSY, TOCSY, NOESY, ¹³C-HSQC and ¹⁵N-HSQC) for **TPI-2**. The determined solution structures revealed that a total of 136 NOE distance restraints (including 8 long-range NOEs) and 22 dihedral restraints, 20 lowest energy structures selected from 100 calculated structures were observed with an all heavy atom RMSD (residue 5–14) of 1.317 Å (ESI Table S2 and Fig. S15†). The NOESY cross peaks and NMR structure showed that **TPI-2** incorporated the correct Cys7–Cys12 ether bond connectivity (Fig. 2d). Furthermore, we also observed the similar chemical shifts for Cα–H of **TPI-2** (The residue Lys1 subject to fast protein exchange) compared with native **TPI-1**^{4b} (Fig. S13†), except for those corresponding to the two replaced Cys residues, thus confirming that **TPI-2** maintained a three dimensional structure similar to the **TPI-1**.

Antimicrobial assays were then used to ascertain the biological activity of the TPI analogs. Three bacterial strains, including two Gram-positive bacteria (*Bacillus subtilis* and *Staphylococcus epidermidis*) and one Gram-negative bacteria (*Escherichia coli*) were used. The three strains were cultured to 10⁸ CFU at 37 °C using LB medium; and the minimal inhibitory concentration (MIC) of the TPI derivatives tested using the standard two-fold dilution method.¹⁴ Each experiment was repeated three times. The ether-containing **TPI-2** and **TPI-3** had identical antibacterial activity to WT **TPI-1**, exerting significant antibacterial activity against both Gram-positive and Gram-negative bacteria at low concentrations. **TPI-4** had a slightly inferior MIC value for *Bacillus subtilis* compared to **TPI-1**,






Fig. 2 (a) Solid-phase synthetic route for the preparation of ether-containing TPI-2 using diaminodiacid **4a**. (b) HPLC traces and ESI-MS analysis of purified refolded TPI-2. (c) CD spectra of TPI-1, TPI-2 and TPI-3 in water. (d) NMR structure of TPI-1 (right) and ether-containing analogue TPI-2 (left). Disulfides are shown in yellow and the ether bond in red. (e) The structure of side-chain extended ether-containing TPI-3 and different lengths of thioether linkage substituted TPI-1 derivatives TPI-4 and TPI-5.

whereas the antibacterial activity of **TPI-5** incorporating a side-chain containing an extended thioether bond was dramatically decreased, for both Gram-positive and Gram-negative bacteria (Table 1). Collectively, these results indicate that ether bond substitution may exert less of an effect on the activity of disulfide-rich polypeptides than thioether bonds, especially in peptides sensitive to structural alterations such as **TPI-1**.

We also studied the stability of these peptides in a reducing environment. After one hour in aqueous dithiothreitol (DTT, 250 μM) solution, 80% **TPI-1** had been completely reduced to linear peptide, whereas **TPI-2** exhibited less than 40% reduction (Fig. S9†). Thus, the replacement of the disulfide functionality with an ether improves the stability of the parent peptide, as expected.

Although thioether crosslinks are among the most popular disulfide surrogates, they remain susceptible to sulfoxide formation under oxidative conditions, which may influence biological activity. Conotoxin α -ImI was selected as the basis for a study to examine whether ether-bond substitutions are more stable than thioethers in an oxidative environment.⁴⁴ Conotoxin α -ImI analogs α -ImI-1 and α -ImI-2 incorporating different

surrogates for the Cys2–Cys7 disulfide bond (Fig. 3) were readily prepared using **4a** and thioether-containing diaminodiacids, respectively. HPLC and MS analysis found that about 30% α -

Table 1 Structures of different TPI-1 analogs and their minimal inhibitory concentrations (MIC) against several bacterial strains. MIC values were obtained by using the standard two-fold dilution protocol

Compound	X ₁	X ₂	X ₃	<i>B. subtilis</i>	<i>S. aureus</i>	<i>E. coli</i>
TPI-1	S	—	S	4	8	4
TPI-2	O	—	CH ₂	4	8	4
TPI-3	O	CH ₂	CH ₂	4	8	4
TPI-4	S	—	CH ₂	8	8	4
TPI-5	CH ₂	S	CH ₂	16	32	16




Fig. 3 Oxidative stability studies on α -lml-1 and α -lml-2 under 0.1% hydrogen peroxide. After 12 hours, almost all α -lml-2 is oxidized, whereas no oxidation by-products of α -lml-1 were observed. * refers to α -lml-2 in which thioether is oxidized to sulfoxide.

lml-2 was oxidized to sulfoxide after 4 hours under 0.1% hydrogen peroxide. When the oxidation process was extended to 12 hours, almost all the α -lml-2 was oxidized. Meanwhile, no oxidation by-products of α -lml-1 were observed after 12 hours under the same oxidation conditions (Fig. 3). These results indicate that the ether-substituted peptide is more stable under oxidative conditions than the thioether-containing analog. Therefore, the ether-bond substitution strategy developed herein is expected to replace the thioether bond strategy for disulfide-rich peptides that are sensitive to oxidative conditions.

Conclusions

A selection of cysteine-rich peptides incorporating an ether-bond as a disulfide surrogate have been efficiently synthesized using a strategy based on diaminiodiacid building blocks, obtained by the stereoselective ring-opening addition reaction of an aziridine skeleton with a hydroxy group. NMR studies suggested that these ether-containing derivatives exhibited very small change of their tertiary structures. The ether analog of the bacteriostatic peptide **TPI-2** was found to be more stable under

reducing conditions than wildtype **TPI-1**, but equally bioactive. Also, the ether-containing conotoxin analog was more stable in an oxidative environment compared to an analog incorporating a thioether. Further studies to explore the scope of this strategy for the improvement of the properties of cysteine-rich peptides are underway.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the National Key R&D Program of China (2017YFA0505400 and 2017YFA0505200), the National Natural Science Foundation of China (No. 91753205, 21877024, 21977089, 81621002, 31971152 and 21621003), the Fundamental Research Funds for the Central Universities (JZ2019HGPB0105). Bayer AG would like to acknowledge Professor Dr Ulrich Koert from the Philipps University of Marburg for useful scientific discussions.

Notes and references

- (a) W. J. Wedemeyer, E. Welker and M. Narayan, *Biochemistry*, 2000, **39**(15), 4207–4216; (b) A. Henninot, J. C. Collins and J. M. Nuss, *J. Med. Chem.*, 2018, **61**, 1382–1414; (c) M. Góngora-Benítez, J. Tulla-Puche and F. Albericio, *Chem. Rev.*, 2014, **114**, 901–926.
- (a) J. Gehrmann, P. F. Alewood and D. J. Craik, *J. Mol. Biol.*, 1998, **278**, 401–415; (b) V. Laverne, R. J. Taft and P. F. Alewood, *Curr. Top. Med. Chem.*, 2012, **12**, 1514–1533.
- (a) C. J. Armishaw, N. L. Daly, S. T. Nevin, D. J. Adams, D. J. Craik and P. F. Alewood, *J. Biol. Chem.*, 2006, **281**, 14136–14143; (b) J.-Y. Chang, B.-Y. Lu and L. Li, *Anal. Biochem.*, 2005, **342**, 78–85; (c) K. Hu, W. Xiong, C. J. Sun, C. Wang, J. X. Li, F. Yin, Y. X. Jiang, M.-R. Zhang, Z. Li, X. W. Wang and Z. G. Li, *CCS Chem.*, 2020, **2**, 42–51.
- (a) Z. Dekan, I. Vetter, N. L. Daly, D. J. Craik, R. J. Lewis and P. F. Alewood, *J. Am. Chem. Soc.*, 2011, **133**, 15866–15869; (b) H. K. Cui, Y. Guo, F. L. Feng, H. N. Chang, Y. J. Wang, F. M. Wu, C. Tian and L. Liu, *Angew. Chem., Int. Ed.*, 2013, **52**, 9558–9562; (c) Y. Guo, D. M. Sun, F. L. Wang, Y. He, L. Liu and C. L. Tian, *Angew. Chem., Int. Ed.*, 2015, **54**, 14276–14281; (d) C. M. B. K. Kourra and N. Cramer, *Chem. Sci.*, 2016, **7**, 7007; (e) S. S. Sun, J. Y. Chen, R. Zhao, D. Bierer, J. Wang, G. M. Fang and Y. M. Li, *Tetrahedron Lett.*, 2019, **60**, 1197–1201; (f) Q. Qu, S. Gao, F. Wu, M. Zhang, Y. Li, L. Zhang, D. Bierer, C. Tian, J. Zheng and L. Liu, *Angew. Chem., Int. Ed.*, 2020, **59**, 6037; (g) H. Lin, Y. Jiang, Q. Zhang, K. Hu and Z. G. Li, *Chem. Commun.*, 2016, **52**, 10389–10391; (h) K. Hu, H. Geng, Q. Z. Zhang, Q. S. Liu, M. S. Xie, C. J. Sun, W. J. Li, H. C. Lin, F. Jiang, T. Wang, Y. D. Wu and Z. G. Li, *Angew. Chem., Int. Ed.*, 2016, **55**, 8013–8017; (i) Y. Tian, J. X. Li, H. Zhao, X. Z. Zeng, D. Y. Wang, Q. S. Liu, X. G. Niu, X. H. Huang, N. H. Xu and Z. G. Li, *Chem. Sci.*, 2016, **7**, 3325–3330; (j)



- T. Wang, J. Fan, X. X. Chen, R. Zhao, Y. Xu, D. Bierer, L. Liu, Y. M. Li, J. Shi and G. M. Fang, *Org. Lett.*, 2018, **20**(19), 6074–6078; (k) J. Koehbach, M. O'Brien, M. Muttenthaler, M. Miazzi, M. Akcan, A. G. Elliott, N. L. Daly, P. J. Harvey, S. Arrowsmith, S. Gunasekera, T. J. Smith, S. Wray, U. Goransson, P. E. Dawson, D. J. Craik, M. Freissmuth and C. W. Gruber, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 21183–21188.
- 5 (a) K. Arai, T. Takei, M. Okumura, S. Watanabe, Y. Amagai, Y. Asahina, L. Moroder, H. Hojo, K. Inaba and M. Iwaoka, *Angew. Chem., Int. Ed.*, 2017, **56**, 5522–5526; (b) K. Medini, P. W. R. Harris, A. Menorca, K. Hards, G. M. Cook and M. A. Brimble, *Chem. Sci.*, 2016, **7**, 2005–2010; (c) M. Muttenthaler, S. T. Nevin, A. A. Grishin, S. T. Ngo, P. T. Choy, N. L. Daly, S.-H. Hu, C. J. Armishaw, C.-I. Wang, R. J. Lewis, J. L. Martin, P. G. Noakes, D. J. Craik, D. J. Adams and P. F. Alewood, *J. Am. Chem. Soc.*, 2010, **132**, 3514–3522; (d) S. Fiori, S. Pegoraro, S. Rudolph-Böhner, J. Cramer and L. Moroder, *Biopolymers*, 2000, **53**, 550–564; (e) S. Pegoraro, S. Fiori, S. Rudolph-Böhner, T. X. Watanabe and L. Moroder, *J. Mol. Biol.*, 1998, **284**, 779–792; (f) Y. Z. Yin, Q. R. Fei, W. D. Liu, Z. R. Li, H. Suga and C. L. Wu, *Angew. Chem., Int. Ed.*, 2019, **58**, 4880–4885; (g) C. Zuo, W.-W. Shi, X.-X. Chen, M. Glatz, B. Riedl, I. Flamme, E. Pook, J. Wang, G.-M. Fang, D. Bierer and L. Liu, *Sci. China: Chem.*, 2019, **62**, 1371–1378.
- 6 (a) K. Holland-Nell and M. Meldal, *Angew. Chem., Int. Ed.*, 2011, **50**, 5204–5206; (b) M. Empting, O. Avrutina, R. Meusinger, S. Fabritz, M. Reinwarth, M. Biesalski, S. Voigt, G. Buntkowsky and H. Kolmar, *Angew. Chem., Int. Ed.*, 2011, **50**, 5207–5211; (c) A. White, S. de Veer, G. Wu, P. Harvey, K. Yap, G. J. King and D. Craik, *Angew. Chem., Int. Ed.*, 2020, **59**, 11273–11277.
- 7 (a) M. A. Hossain, K. J. Rosengren, S. Zhang, R. A. D. Bathgate, G. W. Tregear, B. J. van Lierop, A. J. Robinson and J. D. Wade, *Org. Biomol. Chem.*, 2009, **7**, 1547–1553; (b) C. A. Macrauld, J. Illesinghe, B. J. Van Lierop, L. Amanda, M. Chebib, B. G. Livett, A. J. Robinson and R. S. Norton, *J. Med. Chem.*, 2009, **52**, 755; (c) T. Wang, Y. F. Kong, Y. Xu, J. Fan, H. J. Xu, D. Bierer, J. Wang, J. Shi and Y. M. Li, *Tetrahedron Lett.*, 2017, **58**, 3970; (d) F. L. Feng, Y. Guo, S. J. Li and Y. M. Li, *Org. Biomol. Chem.*, 2015, **13**, 6286–6290; (e) Y. Wu, Y. H. Li, X. Li, Y. Zou, H. L. Liao, L. Liu, Y. G. Chen, D. Bierer and H. G. Hu, *Chem. Sci.*, 2017, **8**, 7368; (f) M. Pan, Q. Y. Zheng, S. Gao, Q. Qu, Y. Y. Yu, M. Wu, H. Lan, Y. L. Li, S. L. Liu, J. B. Li, D. M. Sun, L. N. Lu, T. Wang, W. H. Zhang, J. W. Wang, Y. M. Li, H.-G. Hu, C. L. Tian and L. Liu, *CCS Chem.*, 2019, **1**, 476–489.
- 8 (a) G. M. Williams, K. Lee, X. Li, G. J. Cooper and M. A. Brimble, *Org. Biomol. Chem.*, 2015, **13**, 4059; (b) M. A. Hossain, L. M. Haugaard-Kedstrom, K. J. Rosengren, R. A. D. Bathgate and J. D. Wade, *Org. Biomol. Chem.*, 2015, **13**, 10895.
- 9 (a) A. Williamson, *Justus Liebigs Ann. Chem.*, 1851, **77**, 37; (b) S. Mandal, S. Mandal, S. K. Ghosh, P. Sar, P. Ghosh, R. Saha and B. Saha, *RSC Adv.*, 2016, **6**, 69605.
- 10 (a) X. E. Hu, *Tetrahedron*, 2004, **60**, 2701–2743; (b) D. Tanner, *Angew. Chem., Int. Ed. Engl.*, 1994, **33**, 599–619; (c) B. A. BhanuPrasad, G. Sekar and V. K. Singh, *Tetrahedron Lett.*, 2000, **41**, 4677–4679; (d) H. Q. Liu, V. R. Pattabiraman and J. C. Vederas, *Org. Lett.*, 2007, **9**, 4211–4214; (e) C. C. Chen, S. Gao, H. S. Ai, Q. Qu, C. Tian and Y. M. Li, *Sci. China: Chem.*, 2018, **61**, 702–707.
- 11 B. McKeever and G. Pattenden, *Tetrahedron*, 2003, **59**, 2071–2712.
- 12 M. Muttenthaler, A. Andersson, A. D. de Araujo, Z. Dekan, R. J. Lewis and P. F. Alewood, *J. Med. Chem.*, 2010, **53**, 8585–8596.
- 13 (a) T. Nakamura, H. Furunaka, T. Miyata, F. Tokunaga, T. Muta, S. Iwanaga, M. Niwa, T. Takao and Y. Shimonishi, *J. Biol. Chem.*, 1988, **263**, 16709; (b) H. Tamamura, R. Ioma, M. Niwa, S. Funakoshi, T. Murakami and N. Fujii, *Chem. Pharm. Bull.*, 1993, **41**, 978.
- 14 C. Ramalingan, I.-S. Lee and Y.-W. Kwak, *Chem. Pharm. Bull.*, 2009, **57**, 591.

